Ignite Creation Date:
2025-12-25 @ 4:27 AM
Ignite Modification Date:
2026-02-02 @ 1:17 AM
Study NCT ID:
NCT06239220
Status:
RECRUITING
Last Update Posted:
2025-08-27
First Post:
2024-01-25
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
PD-L1 t-haNK, N-803 IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
Sponsor:
Glenn J. Hanna
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Head and Neck Cancer | View |
| None | Head and Neck Squamous Cell Carcinoma | View |
| None | Metastatic Head and Neck Cancer | View |
| None | Recurrent Head and Neck Cancer | View |
| None | Metastatic Head-and-neck Squamous-cell Carcinoma | View |
| None | Recurrent Head and Neck Squamous Cell Carcinoma | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Head and Neck Cancer | View |
| None | Head and Neck Squamous Cell Carcinoma | View |
| None | Metastatic Head and Neck Cancer | View |
| None | Recurrent Head and Neck Cancer | View |
| None | Metastatic Head-and-neck Squamous-cell Carcinoma | View |
| None | Recurrent Head and Neck Squamous Cell Carcinoma | View |